Registration Details
Use of non-human primates (NHPs) continues to be necessary as part of the drug development process for various reasons, including current regulatory requirements and scientific justifications of human relevance, to ensure the safety of new pharmaceuticals in humans. With the increase in the development of biotherapeutics within the pharmaceutical industry in recent years, the number of NHPs used for testing has also increased. However, due to the COVID-19 pandemic and the concomitant export ban from China, there is a current NHP shortage.
Discover an overview of all the NC3Rs activities and recommendations in this area on our resource page: Minimising non-human primate use in drug development.
Webinar details
The aim of this webinar is to provide an overview of the opportunities that are currently available or being considered to minimise NHP use in drug development. This includes the work of various industry consortia (IQ DruSafe and NHP reuse Working Group, BioSafe and EFPIA), on diverse aspects to minimise NHP use whilst continuing to develop new medicines for patients.
This webinar is relevant for regulatory and industry scientists interested in reducing the use of NHPs in drug development. There will be a panel discussion at the end of the webinar, with an opportunity for audience members to ask questions.
The agenda for the webinar is below:
| Time | Agenda Item |
|---|---|
| 14.00 – 14.10 |
Welcome and introductions Noel Dybdal, Genentech (CHAIR) |
| 14.10 – 14.35 |
Recommendations for minimising NHP use from NC3Rs working groups Helen Prior, NC3Rs |
| 14.35 – 15.00 |
DruSafe initiatives supporting conservation of NHPs in drug development Joanne Birkebak, Gilead Sciences |
| 15.00 – 15.25 |
Reuse of protein non-naïve monkeys in pharmaceutical research and development Charles Mattis, AbbVie |
| 15.25 – 15.35 | Break |
| 15.35 – 16.00 |
NHPs in the PKPD evaluation of biologics: needs and options to reduce, refine and replace. A BioSafe white paper Hongbin Yu, Boehringer-Ingelheim and Karelle Menochet, UCB |
| 16.00 – 16.25 |
Analysis of EFPIA Survey 2022: impact of current NHP shortage on the pharma industry Fred Brouta, UCB |
| 16.25 – 16.55 |
Panel discussion and audience Q&A |
| 16.55 – 17.00 |
Concluding remarks Noel Dybdal (Genentech) |
A recording of this webinar will be made available to delegates after the meeting.